Comorbid Conditions in ADHD
Research type
Research Study
Full title
Pilot randomized-control phase-IIa trial on the prevention of comorbid depression and obesity in attention-deficit/hyperactivity disorder (PROUD)
IRAS ID
207226
Contact name
J Kuntsi
Contact email
Sponsor organisation
University Hospital Frankfurt, Johann Wolfgang Goethe Universitaet, Frankfurt am Main
Clinicaltrials.gov Identifier
DRKS0001166, German Clinical Trials Register registration number; U111111921172, Universal Trial Number
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
The risk for comorbid obesity and major depressive disorder is increased in adolescents and adults with ADHD, and adolescent ADHD predicts adult obesity and major depressive disorder. Bright light therapy (BLT) improves day-night rhythm and is an established therapy for major depression in adolescents and adults. Exercise prevents and reduces obesity in adolescents and adults and also improves depressive symptoms. Interestingly, a reinforcement-based intervention using a mobile health app (m-Health) resulted in improved effects on weight-loss in obesity. The aim of the current pilot randomized-controlled (RCT) Phase-IIa study is to establish feasibility and effect sizes of two kinds of interventions, BLT and exercise, in combination with m-Health based monitoring and reinforcement in adolescents and young adults aged 14 to 30 years old with ADHD, targeting the prevention of depressive symptoms. In addition, effects on ADHD specific psychopathology, self-reported health related quality of life, obesity and several body related measures, such as blood pressure, measures of strength and fitness are explored.
REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
17/LO/0958
Date of REC Opinion
11 Jul 2017
REC opinion
Further Information Favourable Opinion